A phase II study to evaluate efficacy and safety of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancer

Trial Profile

A phase II study to evaluate efficacy and safety of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2016 Primary endpoint (Progression-free survival) has been met, according to the results presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 09 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top